SemperVirens Venture Capital | Activity | F4

Team Portfolio Raise Champions Essays

F4/SemperVirens Venture Capital/Activity

SemperVirens Venture Capital Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Talk

SemperVirens hosted its Summit on September 17, 2026 in NYC, bringing together founders, investors, and allocators for conversations on AI investing, growth-stage metrics, and building in complex markets.

SemperVirens Venture Capital

SemperVirens Venture CapitalSemperVirens Venture Capital

sempervirensvc.com

Added recently

Investment

SemperVirens Venture Capital's latest investment was on 15-Sep-2026 in Thatch, a company within the Financial Services industry, as reported by PitchBook.

Thatch

Thatch SemperVirens Venture Capital

Added recently

Exit

SemperVirens portfolio company Cylinder had an exit on September 1, 2026, as reported by CBInsights.

Cylinder

Cylinder SemperVirens Venture Capital

Added recently

Essay

SemperVirens published its 2025 Year in Review report, covering portfolio milestones, ecosystem growth, and key metrics including $200M+ directly influenced ARR, 190M+ unique lives reached, 5,500+ customer intros, and 200+ executive advisors.

SemperVirens Venture Capital

SemperVirens Venture CapitalSemperVirens Venture Capital

sempervirensvc.com

sempervirensvc.com

sempervirensvc.com

sempervirensvc.com

Added recently

Exit

Portfolio company Cocoon acquired.

Cocoon

Cocoon SemperVirens Venture Capital

pitchbook.comAPR 14, 2026

APR 14, 2026

Team Change

Colin Tobias elevated to General Partner and Raquel Scott promoted to Principal as SemperVirens deepens its AI-workforce focus; firm now at $400M+ AUM and 75+ portfolio companies.

Colin Tobias elevated to General Partner; Raquel Scott promoted to Principal

SemperVirens Venture Capital

vcaonline.comDEC 3, 2025

DEC 3, 2025

Essay

SemperVirens outlined 10 investment themes for 2026 centering on AI agents as digital labor, AI-native HCM platforms, broker/P&C automation, healthcare cost containment, pharma spend reduction, and AI governance.

2026 Investment Themes: AI Agents, HCM, and Healthcare Cost Containment

SemperVirens Venture Capital

sempervirensvc.comDEC 2, 2025

DEC 2, 2025

Investment

Co-led Trial Library's $10M Series A to expand AI-enabled clinical trial access.

Trial Library

Trial Library SemperVirens Venture Capital

vvdailypress.comDEC 2, 2025

DEC 2, 2025

Investment

Participated in Empathy's $72M Series C for end-of-life care services.

Empathy

Empathy SemperVirens Venture Capital

empathy.comMAY 29, 2025

MAY 29, 2025